Varicella Zoster Virus IgG Blood Test kit and immunosuppressed patient consultation

Health-hub

Protecting the Vulnerable: VZV Immunity and Immunosuppression

Our immune system is our body’s primary defence against infection. However, for individuals with weakened immune systems—whether due to medical conditions, treatments like chemotherapy, or immunosuppressive medications—this defence is compromised. For these individuals, common infections that might cause only mild illness in others can pose a significant threat. The varicella zoster virus (VZV), responsible for chickenpox and shingles, is one such infection where understanding immunity is critical for protecting vulnerable patients.

The Heightened Risk of VZV

In immunocompetent individuals, a primary VZV infection (chickenpox) is usually a self-limiting illness. However, for those who are immunosuppressed, the virus can cause severe, disseminated disease. Complications can include severe pneumonia, hepatitis, and encephalitis, which can be life-threatening. [1]

Because the risks are so high, preventing primary VZV infection in susceptible immunosuppressed individuals is a major clinical priority. This requires a clear understanding of the patient’s immune status and a proactive approach to managing potential exposures.

Assessing Immunity in Immunosuppressed Patients

For the general population, a history of chickenpox is often sufficient evidence of immunity. However, this is not the case for immunosuppressed individuals. According to the UK Health Security Agency (UKHSA), a history of previous infection or vaccination is not a reliable indicator of immunity in this group. [2]

Therefore, laboratory testing is essential. A VZV IgG blood test is used to measure the level of antibodies against the virus. The UKHSA guidelines specify that quantitative antibody testing is recommended, and individuals with VZV IgG levels below 150 mIU/ml may be considered susceptible and require intervention if exposed to the virus. [2]

Managing Exposure and Post-Exposure Prophylaxis

If a susceptible immunosuppressed individual comes into contact with someone who has chickenpox or shingles, urgent medical assessment is required. The UKHSA provides clear guidelines on post-exposure prophylaxis (PEP) to attenuate the disease and reduce the risk of severe complications. [2]

Currently, oral antiviral medications, such as aciclovir or valaciclovir, are the first choice of PEP for susceptible immunosuppressed individuals. [2] These medications must be administered within a specific timeframe following exposure, highlighting the importance of knowing one’s immune status in advance to facilitate rapid decision-making.

Proactive Health Management with Clinilabs

For individuals managing complex health conditions or undergoing immunosuppressive treatments, knowledge is a vital component of care. Understanding your VZV immune status allows you and your healthcare team to plan effectively and respond swiftly to potential risks.

The Varicella Zoster Virus IgG Blood Test from Clinilabs can help provide insight into your current level of immunity. This information may support informed conversations with a healthcare professional regarding your specific risks and the appropriate management strategies. By taking a proactive approach to understanding your health data, you can better protect yourself and navigate your healthcare journey with greater confidence.